

Orly Vardeny

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10877430/publications.pdf>

Version: 2024-02-01

49
papers

8,086
citations

185998

28
h-index

233125

45
g-index

49
all docs

49
docs citations

49
times ranked

11813
citing authors

#	ARTICLE	IF	CITATIONS
1	Coronavirus Disease-2019 and Heart Failure: A Scientific Statement From the Heart Failure Society of America. <i>Journal of Cardiac Failure</i> , 2022, 28, 93-112.	0.7	15
2	Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 184-197.	1.9	75
3	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2022, 145, 101161CIR0000000000001063.	1.6	756
4	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2022, 79, e263-e421.	1.2	774
5	Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19. <i>JACC: Heart Failure</i> , 2021, 9, 65-73.	1.9	93
6	Complications in Patients With COVID-19—Reply. <i>JAMA Cardiology</i> , 2021, 6, 360.	3.0	12
7	Serum potassium and outcomes in heart failure with preserved ejection fraction: a post hoc analysis of the PARAGON-HF trial. <i>European Journal of Heart Failure</i> , 2021, 23, 776-784.	2.9	12
8	Spirolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1211-1221.	1.2	19
9	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. <i>European Journal of Heart Failure</i> , 2021, 23, 352-380.	2.9	630
10	Influenza vaccination: a “shot” at INVESTing in cardiovascular health. <i>European Heart Journal</i> , 2021, 42, 2015-2018.	1.0	8
11	Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1518-1524.	2.9	20
12	Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 330-343.	1.2	90
13	Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Na ⁺ ve With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e020474.	1.6	1
14	Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT. <i>European Journal of Heart Failure</i> , 2021, , .	2.9	5
15	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2020, 141, 338-351.	1.6	244
16	Recognition and Initial Management of Fulminant Myocarditis. <i>Circulation</i> , 2020, 141, e69-e92.	1.6	368
17	Cardiovascular implications of COVID-19 versus influenza infection: a review. <i>BMC Medicine</i> , 2020, 18, 403.	2.3	47
18	Applying the Lessons of Influenza to COVID-19 During a Time of Uncertainty. <i>Circulation</i> , 2020, 141, 1667-1669.	1.6	16

#	ARTICLE	IF	CITATIONS
19	Potential Effects of Coronaviruses on the Cardiovascular System. <i>JAMA Cardiology</i> , 2020, 5, 831.	3.0	1,469
20	Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. <i>New England Journal of Medicine</i> , 2020, 382, 1653-1659.	13.9	1,732
21	Effects of hydroxychloroquine treatment on QT interval. <i>Heart Rhythm</i> , 2020, 17, 1930-1935.	0.3	51
22	Interactions Between Influenza and Heart Failure Hospitalizations—Diagnostic and Pathogenetic Issues—Reply. <i>JAMA Cardiology</i> , 2019, 4, 950.	3.0	0
23	Association of Influenza-like Illness Activity With Hospitalizations for Heart Failure. <i>JAMA Cardiology</i> , 2019, 4, 363.	3.0	97
24	Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 337-341.	2.9	129
25	Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 1022-1028.	1.9	6
26	Influenza and Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 118-120.	1.9	17
27	Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril. <i>Circulation: Heart Failure</i> , 2018, 11, e004745.	1.6	55
28	PARADIGM-HF Trial: Secondary Analyses Address Unanswered Questions. <i>Pharmacotherapy</i> , 2018, 38, 284-298.	1.2	9
29	High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. <i>American Heart Journal</i> , 2018, 202, 97-103.	1.2	38
30	Vaccination Trends in Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 844-855.	1.9	30
31	Influenza vaccination: a one-shot deal to reduce cardiovascular events. <i>European Heart Journal</i> , 2017, 38, ehw560.	1.0	22
32	Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril. <i>JAMA Cardiology</i> , 2017, 2, 79.	3.0	143
33	Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. <i>European Journal of Heart Failure</i> , 2017, 19, 792-799.	2.9	34
34	Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2016, 18, 1228-1234.	2.9	173
35	Association of Weight and Body Composition on Cardiac Structure and Function in the ARIC Study (Atherosclerosis Risk in Communities). <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	59
36	Influenza Vaccination in Patients With Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 152-158.	1.9	112

#	ARTICLE	IF	CITATIONS
37	Response to Letter Regarding Article, "Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study"; Circulation: Heart Failure, 2015, 8, 1010-1010.	1.6	0
38	Angiotensin receptor-neprilysin inhibitors in heart failure: a shifting paradigm. Evidence-Based Medicine, 2015, 20, 61-61.	0.6	0
39	Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease. Circulation: Heart Failure, 2015, 8, 448-454.	1.6	68
40	Incidence, Predictors, and Outcomes Related to Hypo- and Hyperkalemia in Patients With Severe Heart Failure Treated With a Mineralocorticoid Receptor Antagonist. Circulation: Heart Failure, 2014, 7, 573-579.	1.6	155
41	Lack of Persistence of Influenza Vaccine Antibody Titers in Patients With Heart Failure. Journal of Cardiac Failure, 2014, 20, 105-109.	0.7	15
42	Combined Neprilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure. JACC: Heart Failure, 2014, 2, 663-670.	1.9	129
43	Nonprescription Medication Use in Patients With Heart Failure: Assessment Methods, Utilization Patterns, and Discrepancies With Medical Records. Journal of Cardiac Failure, 2013, 19, 811-815.	0.7	15
44	Double dose vs. standard dose influenza vaccination in patients with heart failure: a pilot study. European Journal of Heart Failure, 2013, 15, 560-564.	2.9	25
45	Influence of Baseline and Worsening Renal Function on Efficacy of Spironolactone in Patients With Severe Heart Failure. Journal of the American College of Cardiology, 2012, 60, 2082-2089.	1.2	218
46	Decreased T-Cell Responses to Influenza Vaccination in Patients with Heart Failure. Pharmacotherapy, 2010, 30, 10-16.	1.2	21
47	Decreased Immune Responses to Influenza Vaccination in Patients With Heart Failure. Journal of Cardiac Failure, 2009, 15, 368-373.	0.7	40
48	Cyclooxygenase-2 Inhibitors, Nonsteroidal Anti-inflammatory Drugs, and Cardiovascular Risk. Cardiology Clinics, 2008, 26, 589-601.	0.9	37
49	Aminoglycosides and other nonsense suppression therapies for the treatment of dystrophinopathy. The Cochrane Library, 0, , .	1.5	2